ViiV Healthcare

ViiV Healthcare is a British multinational pharmaceutical company specializing in the research and development of medicines to treat and prevent HIV/AIDS. Its global headquarters is located in London. The company was created as a joint venture by GSK and Pfizer in November 2009, with both companies transferring their HIV assets to the new company.[1] In 2012, Shionogi joined the company. As of December 2023, 76.5% of the company is owned by GSK, 13.5% by Pfizer and 10% by Shionogi.[2] According to The Financial Times, the company's co-ownership structure may change depending on the achievement of certain milestones.[1]

ViiV Healthcare's products have a market share of approximately 32% of the global HIV therapy market, making it the second-largest healthcare company in the sector, after Gilead Sciences.[3]

ViiV Healthcare's global headquarters are in London in the United Kingdom, and the company has sites in a number of other countries including the United States, Australia, Belgium, Canada, France, Germany, Italy, Japan, Mexico, the Netherlands, Portugal, Puerto Rico, Russia, Spain and Switzerland.[4]

Products

The company markets 17 products:[5]

• Nucleoside reverse transcriptase inhibitors (NRTIs):
• abacavir (brand name Ziagen)
• lamivudine (brand names Epivir and 3TC)
• zidovudine (brand name Retrovir and AZT)
• Non-nucleoside reverse transcriptase inhibitors (NNRTIs):
• delavirdine (brand name Rescriptor, no longer available[6])
• Attachment inhibitors
• fostemsavir (brand name Rukobia)
• Integrase strand transfer inhibitors (INSTIs):
• dolutegravir (brand name Tivicay)
• cabotegravir (brand names Apretude [as a single agent indicated for PrEP]; and Vocabria/Cabenuva [when co-administered with rilpivirine for HIV treatment – in partnership with Janssen Pharmaceuticals])
• Protease inhibitors:
• fosamprenavir (brand names Lexiva and Telzir)
• nelfinavir (brand name Viracept)
• Entry inhibitors:
• maraviroc (brand names Selzentry and Celsentri)
• Antiretroviral fixed-dose combinations, including several single-pill regimens:
• abacavir/lamivudine (brand names Epzicom and Kivexa)
• abacavir/lamivudine/zidovudine (brand name Trizivir)
• lamivudine/zidovudine (brand name Combivir)
• abacavir/dolutegravir/lamivudine (brand name Triumeq)
• dolutegravir/lamivudine (brand name Dovato)
• dolutegravir/rilpivirine (brand name Juluca – in partnership with Janssen Pharmaceuticals)

Treatment access programs

ViiV Healthcare has stated that it will continue the not-for-profit pricing schemes that Pfizer and GlaxoSmithKline had been involved in prior to the setting up of the company. This program covers all low- and middle-income countries, as well as all of Sub-Saharan Africa.[7]

The company has also granted voluntary licenses to 14 generics companies to enable the low-cost manufacture and sale of generic versions of the company's products in specific countries and/or regions.[7][8]

In March 2020, ViiV Healthcare announced the initiation of a study in partnership with University of South Carolina's Ryan White Program to determine the effectiveness of ride-sharing services in improving access to care for people living with HIV.[9]

See also

• Pharmaceutical industry in the United Kingdom
• List of pharmaceutical companies